drugset / Trial / NCT06929195
Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
Phase 1
Completed
16 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such as advanced gastric/gastroesophageal junction cancer.
Timeline
- Start
- 2025-05-16
- Primary completion
- 2026-04-10
- Completion
- 2026-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2210 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | TQB2210 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | TQB2210 | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | TQB2210 | Monoclonal antibody | 16 mg/kg | Intravenous |
| Subject | TQB2210 | Monoclonal antibody | 24 mg/kg | Intravenous |